APA (7th ed.) Citation

Shao, H., Alsaleh, A. J. O., Dex, T., Lew, E., & Fonseca, V. (2022). Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US. Diabetes Therapy, 13(9), 1659. https://doi.org/10.1007/s13300-022-01300-5

Chicago Style (17th ed.) Citation

Shao, Hui, Abdul Jabbar Omar Alsaleh, Terry Dex, Elisheva Lew, and Vivian Fonseca. "Cost-Effectiveness of IGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US." Diabetes Therapy 13, no. 9 (2022): 1659. https://doi.org/10.1007/s13300-022-01300-5.

MLA (9th ed.) Citation

Shao, Hui, et al. "Cost-Effectiveness of IGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US." Diabetes Therapy, vol. 13, no. 9, 2022, p. 1659, https://doi.org/10.1007/s13300-022-01300-5.